CoChat

Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation

Open access
Van Allen, Eliezer M., Golay, Hadrien G., Liu, Yan, Koyama, Shohei, Wong, Karrie, Taylor-Weiner, Amaro, Giannakis, Marios, Harden, Maegan, Rojas-Rudilla, Vanesa, Chevalier, Aaron, Thai, Tran, Lydon, Christine, Mach, Stacy, Avila, Ada G., Wong, Joshua A., Rabin, Alexandra R., Helmkamp, Joshua, Sholl, Lynette, Carter, Scott L., Oxnard, Geoffrey, Janne, Pasi, Getz, Gad, Lindeman, Neal, Hammerman, Peter S., Garraway, Levi A., Hodi, F. Stephen, Rodig, Scott J., Dranoff, Glenn, Wong, Kwok-Kin, Barbie, David A. · 2015 · Cancer Immunology Research
Cited by 69

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. We performed comprehensive genomic profiling on a tumor and germline sample from a patient with refractory lung adenocarcinoma who achieved marked long-term clinical benefit from anti–PD-L1 therapy. We discovered activating somatic and germline amino acid variants in JAK3 that promoted PD-L1 induction in lung cancer cells and in the tumor immune microenvironment. These findings suggest that genomic alterations that deregulate cytokine receptor signal transduction could contribute to PD-L1 activation and engagement of the PD-1 immune checkpoint in lung cancer. Cancer Immunol Res; 3(8); 855–63. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-15-0024

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 69

Metadata

Authors
Van Allen, E. M., Golay, H. G., Liu, Y., Koyama, S., Wong, K., Taylor-Weiner, A., Giannakis, M., Harden, M., Rojas-Rudilla, V., Chevalier, A., Thai, T., Lydon, C., Mach, S., Avila, A. G., Wong, J. A., Rabin, A. R., Helmkamp, J., Sholl, L., Carter, S. L., Oxnard, G., Janne, P., Getz, G., Lindeman, N., Hammerman, P. S., Garraway, L. A., Hodi, F. S., Rodig, S. J., Dranoff, G., Wong, K.-K., & Barbie, D. A.
Venue
Cancer Immunology Research
Published
2015-08-01
Volume
3
Issue
8
Pages
855-863
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2135163858
Cited by
69
References
4
FWCI
4.94
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. https://app.cochat.ai/papers/10.1158/2326-6066.cir-15-0024
The paper
Van Allen, E. M., Golay, H. G., Liu, Y., Koyama, S., Wong, K., Taylor-Weiner, A., Giannakis, M., Harden, M., Rojas-Rudilla, V., Chevalier, A., Thai, T., Lydon, C., Mach, S., Avila, A. G., Wong, J. A., Rabin, A. R., Helmkamp, J., Sholl, L., Carter, S. L., . . . Barbie, D. A. (2015). Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-15-0024

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.